The aims of Inhibitors of Protein Kinases and Protein Phosphatases are to :
- highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors
- to provide a thorough overview of the most remarkable achievements in the field
- to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases
This goal is attained by contributions of leader investigators in the field, who address the issue from different angles.
Contents
General Aspects of PKs Inhibition
- New Design Strategies for Ligands That Target Protein Kinase-Mediated
- Protein–Protein Interactions
Pharmacological Potential and Inhibitors
of Individual Classes of Protein Kinases
- The Paullones: A Family of Pharmacological Inhibitors
of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3
- Pharmacological Potential of p38 MAPK Inhibitors
- Inhibitors of PKA and Related Protein Kinases
- Inhibitors of Protein Kinase CK2: Structural Aspects
- Aminoglycoside Kinases and Antibiotic Resistance
Pharmacological Potential and Inhibitors
of Individual Classes of Protein Phosphatases
- Protein Tyrosine Phosphatases as Therapeutic Targets
- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors
- Biological Validation of the CD45 Tyrosine Phosphatase
as a Pharmaceutical Target
- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity
Inhibitors in Clinical Use or Advanced Clinical Trials
- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin
and Tacrolimus
- Targeted Therapy with Imatinib: An Exception or a Rule?
- Clinical Aspects of Imatinib Therapy
- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase
and the Clinical Aspect of Anti-Rho-Kinase Therapy
- Discovery and Development of Iressa:
- The First in a New Class of Drugs Targeted at the
- Epidermal Growth Factor Receptor Tyrosine Kinase
Index